StudyFinder

A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors

Status: Recruiting

This study aims to evaluate the safety and tolerability of ADRX-0405 in people with advanced cancer and determine the optimal dose for treatment.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• age 18 or older
• Phase 1a: confirmed advanced solid tumors (metastatic castration resistant prostate cancer (mCRPC), gastric cancer (GC), and non-small cell lung cancer (NSCLC))
• Phase 1b: confirmed prostate adenocarcinoma that is confirmed to be castration resistant and that is intolerant/resistant to standard of care (SOC) therapies
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• active and uncontrolled central nervous system metastases
• have received an anticancer or investigational therapy prior to the first dose of study drug
• history of ILD/pneumonitis requiring steroid treatment within the past 2 years, current ILD/pneumonitis, or an active infection requiring systemic antibiotics (prophylactic antibiotics permitted)
• see link to clinicaltrials.gov for complete exclusion criteria
Interventions:

Drug: ADRX-0405

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Cancer

Study Contact: Emmanuel Antonarakis - anton401@umn.edu
Principal Investigator: Emmanuel Antonarakis
Phase: PHASE1
IRB Number: STUDY00024172
See this study on ClinicalTrials.gov

Back